182 related articles for article (PubMed ID: 15876951)
1. Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine.
Claesson BA; Trollfors B; Lagergård T; Knutsson N; Schneerson R; Robbins JB
Pediatr Infect Dis J; 2005 May; 24(5):463-4. PubMed ID: 15876951
[TBL] [Abstract][Full Text] [Related]
2. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants.
Nohynek H; Gustafsson L; Capeding MR; Käyhty H; Olander RM; Pascualk L; Ruutu P
Pediatr Infect Dis J; 1999 Jan; 18(1):25-30. PubMed ID: 9951976
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
4. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
[TBL] [Abstract][Full Text] [Related]
5. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
6. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
[TBL] [Abstract][Full Text] [Related]
9. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
Huebner RE; Nicol M; Mothupi R; Käyhty H; Mbelle N; Khomo E; Klugman KP
Vaccine; 2004 Dec; 23(6):802-6. PubMed ID: 15542205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation.
Vance E; George S; Guinan EC; Wheeler C; Antin JH; Ambrosino DM; Molrine DC
Bone Marrow Transplant; 1998 Oct; 22(8):735-41. PubMed ID: 9827969
[TBL] [Abstract][Full Text] [Related]
11. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.
Booy R; Heath PT; Slack MP; Begg N; Moxon ER
Lancet; 1997 Apr; 349(9060):1197-202. PubMed ID: 9130940
[TBL] [Abstract][Full Text] [Related]
12. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
15. Serum antibodies against haemophilus influenzae type b and tetanus at 2.5 years of age: a follow-up of 2 different regimens of infant vaccination.
Carlsson RM; Claesson BA; Lagergård T; Käyhty H
Scand J Infect Dis; 1996; 28(5):519-23. PubMed ID: 8953685
[TBL] [Abstract][Full Text] [Related]
16. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
[TBL] [Abstract][Full Text] [Related]
17. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
[TBL] [Abstract][Full Text] [Related]
18. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
[TBL] [Abstract][Full Text] [Related]
19. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
[TBL] [Abstract][Full Text] [Related]
20. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age.
Claesson BA; Schneerson R; Lagergård T; Trollfors B; Taranger J; Johansson J; Bryla D; Robbins JB
Pediatr Infect Dis J; 1991 Aug; 10(8):560-4. PubMed ID: 1891286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
